FrançaisAre analysts right about Charles River Laboratories (CRL)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Charles River Laboratories, we replayed every analyst price target of the past 12 months and measured the real outcome: 41% were profitable, average return +22% (133 calls). At 3 months: +6% average return (55% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Jefferies | 14 | 43% | +30% |
| Baird | 10 | 20% | +3% |
| Wells Fargo | 9 | 44% | +25% |
| Citigroup | 9 | 56% | +43% |
| Morgan Stanley | 9 | 44% | +38% |
Frequently asked questions
Is Charles River Laboratories a buy right now?
The analyst consensus on Charles River Laboratories (CRL) is "Buy" (24 bullish, 0 bearish calls over 12 months). This is not advice: historically, 41% of their targets on this stock turned out profitable over 1 year.
What is Charles River Laboratories's price target?
The median 12-month price target is $291 (-2% vs $296), ranging from $219 to $310 (8 analysts).
Are analysts accurate on Charles River Laboratories?
Over 1 year, 41% of analyst targets on Charles River Laboratories were profitable, for an average return of +22% (across 133 timestamped calls). This is JPI Invest's accuracy metric.
What is the Charles River Laboratories stock forecast?
Analysts target a median of $291 within 12 months, i.e. -2% vs the current price. The most bullish targets $310, the most cautious $219.
What is the Charles River Laboratories stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $291, -2%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (41%), and the stock's past trajectory.
Is Charles River Laboratories overvalued?
Detailed valuation data for Charles River Laboratories is available in the interactive analysis.
📊 See the full interactive analysis of Charles River Laboratories →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.